- CEO Kim Ju-hee delivers a keynote speech at the Songdo Innovation New Drug Salon on September 10
- Uniform particles and predictable PK identified as key drivers to competitiveness
- Demonstrating the stability and convenience of drug addiction, hair loss, and obesity treatment platforms
- Curatis factory acquisition ensures mass production infrastructure
[by Ji, Yong Jun] "A drug delivery system (DDS) is fundamentally characterized by its ability to uniformly manufacture drug particles, limit the occurrence of an initial burst drug release after administration, and provide a predictable pharmacokinetic (PK) profile."
This statement was delivered by Kim Ju-hee, CEO of Inventage Lab, during a presentation titled "Latest 인터넷 바카라 사이트 Trends and Application Cases of Specialized Formulations" at the Songdo Innovative New Drug Salon held at Songdo Startup Park in Incheon city on the afternoon of September 10.
인터넷 바카라 사이트s are no longer limited to the development of simple materials. Their application has broadened to encompass antibodies, peptides, proteins, and nucleic acids, thereby making the advent of a new phase in drug delivery technology. "The critical determinant of 인터넷 바카라 사이트 success lies in its controlled release, which enables precise regulation of drug release," Kim emphasized.
Traditional emulsion-based methods employed in 인터넷 바카라 사이트 have been associated with the risk of adverse effects, notably hepatotoxicity, arising from initial burst release caused by uneven particles. To address this limitation, Inventage Lab utilized its microfluidic-based 인터넷 바카라 사이트 platform, IVL-DrugFluidic, which reduced particle size variation to approximately 8%. This technology enabled the company to achieve a stable pharmacokinetic (PK) profile approximating ‘zero-order release,’ a mechanism characterized by the constant release of the drug over time.
This approach has played a pivotal role in mitigating adverse drug reactions, reducing the frequency of administrations, and prolonging treatment duration. Consequently, Korean and international pharmaceutical companies, including Boehringer Ingelheim, Yuhan Corporation, and Daewoong Pharmaceutical, have acknowledged the importance of 인터넷 바카라 사이트, adopting Inventage Lab's technology and pursuing joint research initiatives. According to Inventage Lab, the company has completed eight platform-based out-licensing (L/O) agreements and is currently engaged in five global collaboration projects.
The competitiveness of the platform is being validated through non-clinical and clinical trials. IVL3004 (development code), currently under development as a treatment candidate for drug addiction, exhibited suppression of the initial burst in comparison with the control group, ‘Vivitrol,’ while maintaining a stable PK profile despite a 30% reduction in dosage.
Inventage Labs reported notable improvements in patient safety and administration convenience in the Australian Phase 1 clinical trial of IVL3004, with top-line results announced today. Injection-site adverse effects persisted for 3.8 days and 4.9 days in the IVL3004 treatment group (300 mg and 380 mg, respectively), markedly shorter than the 18.2 days observed with Vivitrol. Moreover, no serious adverse events (SAEs), fatalities, or treatment discontinuations were recorded.
A long-acting injectable formulation of ‘finasteride (marketed as Propecia) for the treatment of hair loss is currently being developed in collaboration with Daewoong Pharmaceutical, with a dosing interval of one to three months. In contrast to existing oral formulations that require daily administration for the suppression of dihydrotestosterone (DHT), this injectable candidate has demonstrated sustained long-term efficacy in clinical observations.
Inventage Lab's 인터넷 바카라 사이트 has also been applied in obesity and metabolic disorder treatments, yielding consistent results. "The application of the Inventage Lab platform to semaglutide (Wegovy) and terzepatide (Mounjaro) achieves gradual and stable PK with a single monthly administration," Kim explained.
Having established high quality through its platform, Kim underscored ‘mass production’ as the key to 인터넷 바카라 사이트's development. She contended that the true measure of 인터넷 바카라 사이트 competitiveness resides not in research outcomes or pilot-scale studies, but in the ability to achieve consistent mass production under Good Manufacturing Practice (GMP). While global pharmaceutical companies acknowledge the technological potential of 인터넷 바카라 사이트, their primary criterion for assessing technological reliability remains the feasibility of mass production.
Earlier this year, Inventage Labs acquired Curatis, thereby securing a GMP-certified facility and establishing a mass production infrastructure. According to Kim, the company’s entry into the 인터넷 바카라 사이트 market, coupled with the development of proprietary equipment and in-house research, enabled it to avoid scale-up challenges by applying identical GMP equipment to its research processes. "Ultimately, ensuring the quality of the 인터넷 바카라 사이트 platform is a fundamental prerequisite, and its true competitiveness is defined at the mass production stage."